Background: Knowing which factors contribute to county-level vulnerability to a human immunodeficiency virus (HIV)/hepatitis C virus (HCV) outbreak, and which counties are most vulnerable, guides public health and clinical interventions. We therefore examined the impact of locally available indicators related to the opioid epidemic on prior national models of HIV/HCV outbreak vulnerability. Methods: Tennessee's 95 counties were the study sample. Predictors from 2012 and 2013 were used, mirroring prior methodology from the US Centers for Disease Control and Prevention (CDC). Acute HCV incidence was the proxy measure of county-level vulnerability. Seventy-eight predictors were identified as potentially predictive for HIV/HCV vulnerability. We used multiple dimension reduction techniques to determine predictors for inclusion and Poisson regression to generate a composite index score ranking county-level vulnerability for HIV/HCV. Results: There was overlap of high-risk counties with the national analysis (25 of 41 counties). The distribution of vulnerability reinforces earlier research indicating that eastern Tennessee is at particularly high risk but also demonstrates that the entire state has high vulnerability. Conclusions: Prior research placed Tennessee among the top states for opioid prescribing, acute HCV infection, and greatest risk for an HIV/HCV outbreak. Given this confluence of risk, the Tennessee Department of Health expanded upon prior work to include more granular, local data, including on opioid prescribing. We also explored nonfatal and fatal overdoses. The more complete statewide view of risk generated, not only in eastern counties but also in the western corridor, will enable local officials to monitor vulnerability and better target resources.
Background: Knowing which factors contribute to county-level vulnerability to a human immunodeficiency virus (HIV)/hepatitis C virus (HCV) outbreak, and which counties are most vulnerable, guides public health and clinical interventions. We therefore examined the impact of locally available indicators related to the opioid epidemic on prior national models of HIV/HCV outbreak vulnerability. Methods: Tennessee's 95 counties were the study sample. Predictors from 2012 and 2013 were used, mirroring prior methodology from the US Centers for Disease Control and Prevention (CDC). Acute HCV incidence was the proxy measure of county-level vulnerability. Seventy-eight predictors were identified as potentially predictive for HIV/HCV vulnerability. We used multiple dimension reduction techniques to determine predictors for inclusion and Poisson regression to generate a composite index score ranking county-level vulnerability for HIV/HCV. Results: There was overlap of high-risk counties with the national analysis (25 of 41 counties). The distribution of vulnerability reinforces earlier research indicating that eastern Tennessee is at particularly high risk but also demonstrates that the entire state has high vulnerability. Conclusions: Prior research placed Tennessee among the top states for opioid prescribing, acute HCV infection, and greatest risk for an HIV/HCV outbreak. Given this confluence of risk, the Tennessee Department of Health expanded upon prior work to include more granular, local data, including on opioid prescribing. We also explored nonfatal and fatal overdoses. The more complete statewide view of risk generated, not only in eastern counties but also in the western corridor, will enable local officials to monitor vulnerability and better target resources.
Authors: Michelle M Van Handel; Charles E Rose; Elaine J Hallisey; Jessica L Kolling; Jon E Zibbell; Brian Lewis; Michele K Bohm; Christopher M Jones; Barry E Flanagan; Azfar-E-Alam Siddiqi; Kashif Iqbal; Andrew L Dent; Jonathan H Mermin; Eugene McCray; John W Ward; John T Brooks Journal: J Acquir Immune Defic Syndr Date: 2016-11-01 Impact factor: 3.731
Authors: Philip J Peters; Pamela Pontones; Karen W Hoover; Monita R Patel; Romeo R Galang; Jessica Shields; Sara J Blosser; Michael W Spiller; Brittany Combs; William M Switzer; Caitlin Conrad; Jessica Gentry; Yury Khudyakov; Dorothy Waterhouse; S Michele Owen; Erika Chapman; Jeremy C Roseberry; Veronica McCants; Paul J Weidle; Dita Broz; Taraz Samandari; Jonathan Mermin; Jennifer Walthall; John T Brooks; Joan M Duwve Journal: N Engl J Med Date: 2016-07-21 Impact factor: 91.245
Authors: Gery P Guy; Kun Zhang; Michele K Bohm; Jan Losby; Brian Lewis; Randall Young; Louise B Murphy; Deborah Dowell Journal: MMWR Morb Mortal Wkly Rep Date: 2017-07-07 Impact factor: 17.586
Authors: Julia Brennan; Caleb Wiedeman; John R Dunn; William Schaffner; Timothy F Jones Journal: Public Health Rep Date: 2019-08-07 Impact factor: 2.792
Authors: Teresa A Chueng; Hansel E Tookes; Megan McLaughlin; Angela M Arcaro-Vinas; David P Serota; Tyler S Bartholomew Journal: Subst Use Misuse Date: 2022-06-10 Impact factor: 2.362
Authors: Toni Hall; Cathy A Jenkins; Todd Hulgan; Sally Furukawa; Megan Turner; Siddharth Pratap; Timothy R Sterling; Mohammad Tabatabai; Vladimir Berthaud Journal: AIDS Res Hum Retroviruses Date: 2019-12-30 Impact factor: 2.205
Authors: Ann M Dennis; Erik Volz; A S Md Simon D W Frost; Mukarram Hossain; Art F Y Poon; Peter F Rebeiro; Sten H Vermund; Timothy R Sterling; Marcia L Kalish Journal: AIDS Res Hum Retroviruses Date: 2018-08-23 Impact factor: 2.205
Authors: Michael Ripperger; Sarah C Lotspeich; Drew Wilimitis; Carrie E Fry; Allison Roberts; Matthew Lenert; Charlotte Cherry; Sanura Latham; Katelyn Robinson; Qingxia Chen; Melissa L McPheeters; Ben Tyndall; Colin G Walsh Journal: J Am Med Inform Assoc Date: 2021-12-28 Impact factor: 7.942
Authors: Charles Marks; Daniela Abramovitz; Christl A Donnelly; Gabriel Carrasco-Escobar; Rocío Carrasco-Hernández; Daniel Ciccarone; Arturo González-Izquierdo; Natasha K Martin; Steffanie A Strathdee; Davey M Smith; Annick Bórquez Journal: Lancet Public Health Date: 2021-06-10
Authors: Jesse L Yedinak; Yu Li; Maxwell S Krieger; Katharine Howe; Colleen Daley Ndoye; Hyunjoon Lee; Anna M Civitarese; Theodore Marak; Elana Nelson; Elizabeth A Samuels; Philip A Chan; Thomas Bertrand; Brandon D L Marshall Journal: Int J Drug Policy Date: 2021-07-31